We are live on ! Find out more

1,474 hedge funds and large institutions have $91.2B invested in Amgen in 2016 Q2 according to their latest regulatory filings, with 112 funds opening new positions, 633 increasing their positions, 503 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more first-time investments, than exits

New positions opened: 112 | Existing positions closed: 60

26% more repeat investments, than reductions

Existing positions increased: 633 | Existing positions reduced: 503

3% more funds holding

Funds holding: 1,4361,474 (+38)

1% more funds holding in top 10

Funds holding in top 10: 8586 (+1)

1% more capital invested

Capital invested by funds: $90.4B → $91.2B (+$722M)

21% less call options, than puts

Call options by funds: $792M | Put options by funds: $1B

Holders
1,474
Holders Change
+38
Holders Change %
+2.65%
% of All Funds
39.24%
Holding in Top 10
86
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+1.18%
% of All Funds
2.29%
New
112
Increased
633
Reduced
503
Closed
60
Calls
$792M
Puts
$1B
Net Calls
-$209M
Net Calls Change
-$50.2M

AMGN Hedge Fund Activity: Q2 2016 in Review

1,474 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Amgen (AMGN) for Q2 2016, worth a combined $91.2B — up 0.8% from $90.4B a quarter earlier.

Buyers outnumbered sellers: 112 funds opened new AMGN positions and 60 closed out — a net gain of 52 holders — while 633 added to existing stakes and 503 trimmed.

The largest buyer was Nordea Investment Management, adding an estimated $241M. The largest seller was Capital Research Global Investors, cutting an estimated $995M.

  • 1,474 institutional investors held Amgen (AMGN) as of Q2 2016, up from 1,436 in Q1 2016.
  • Funds reported $91.2B of Amgen stock for Q2 2016, up 0.8% quarter-over-quarter.
  • 112 funds opened new Amgen positions in Q2 2016 and 60 closed out, a net change of +52 holders.
  • The largest Amgen buyer in Q2 2016 was Nordea Investment Management, an estimated $241M added.
  • The largest Amgen seller in Q2 2016 was Capital Research Global Investors, an estimated $995M sold.

Based on aggregated 13F filings for Q2 2016.